Clinical Trials

Phase 1/2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07328490 2026-03-18

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

120 enrolled

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT05633667 2026-03-17

VELOCITY-Lung

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Phase 1/2 Active not recruiting

Metastatic Urothelial Cancer

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

75 enrolled

Breast Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

70 enrolled

Urothelial Bladder Carcinoma

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Localized Muscle Invasive Bladder Urothelial Carcinoma

NCT05884320 2026-03-11

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Phase 3 Not yet recruiting

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06311214 2026-03-06

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Ovarian Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05581589 2026-02-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

18 enrolled

Urinary Bladder Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

15 enrolled

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04251416 2026-02-17

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

50 enrolled

Endometrial Neoplasms

NCT06963905 2026-02-17

SIMONE

60 enrolled

Triple Negative Breast Neoplasms

NCT04617522 2026-02-11

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Phase 1 Recruiting

30 enrolled

Neoplasm Metastasis, Liver Failure

NCT05186974 2026-02-11

EVOKE-02

193 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT05838521 2026-02-06

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT07393555 2026-02-06

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

117 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

80 enrolled

Triple Negative Breast Neoplasms

NCT03964727 2026-01-30

TROPiCS-03

223 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT06926920 2026-01-30

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT07339059 2026-01-30

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

35 enrolled

Phase 2 Not yet recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07367178 2026-01-28

SATROPIN

30 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07368543 2026-01-28

STORM

216 enrolled

Breast Neoplasms

NCT05327530 2026-01-26

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

256 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

272 enrolled

Phase 2 Enrolling by invitation

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07359404 2026-01-22

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

60 enrolled

Advanced Breast Cancer

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Phase 2 Terminated

2 enrolled 7 charts

Recurrence

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Triple Negative Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

110 enrolled 26 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

640 enrolled

Endometrial Neoplasms

NCT06263543 2025-12-26

SERIES

75 enrolled

Breast Neoplasms

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Phase 1 Recruiting

Phase 1/2 Active not recruiting

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04863885 2025-12-17

Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

46 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

314 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

31 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06612203 2025-12-05

WIN-B

76 enrolled

Advanced Breast Cancer

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

54 enrolled

Phase 3 Active not recruiting

Ovarian Neoplasms, Uterine Neoplasms

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors